All In Biotech

Drug Trial Radar · NCT06375733

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

A Phase Ib/II, Multicenter, Open-label, Single-arm Study to Assess the Safety and Efficacy of GFH009 in Combination With Zanubrutinib in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

51

Planned (sponsor's estimate)

Start

Mar 20, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Conditions

  • Large B-cell Lymphoma

Interventions

  • GFH009Drug

    administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.

  • ZanubrutinibDrug

    administered at 160mg BID oral; 28-day a cycle until disease progresses.

  • GFH009Drug

    the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.

  • ZanubrutinibDrug

    administered at 160mg BID oral; 28-day a cycle until disease progresses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: adverse events(AEs)Time frame: From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose, or until the start of a new anti-tumor therapy,assessed up to 32 months
  2. Phase II: ORRTime frame: From Screening (Day -28 to Day-1) to 30 days ±7 days after the last dose,or until the start of a new anti-tumor therapy, assessed up to 32 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute

    Nanning, China · Recruiting

  • Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.